SHANGHAI, China, Jan. 3 /PRNewswire/ -- Cinpathogen, through its partnership in the Fudan-Cinpathogen Clinical and Molecular Research Center, has begun offering clinical diagnostic technology consulting services to Shanghai area hospitals. For the past four years as part of the Shanghai Health Study, the Center has diagnosed and characterized over 3000 cases of hematopoietic and lymphoid diseases in collaboration with area hospitals and colleagues at Fudan University, the University of Colorado at Denver and Health Sciences Center and the University of Cincinnati. By launching this service, Cinapthogen and the Institute of Biomedical Sciences at Fudan University are ensuring continuous development and enhancement of the clinical diagnostic capabilities in China.
"Though the research project has made a solid landing after seven years of extensive effort and participation, the Fudan-Cinpathogen Clinical and Molecular Research Center's mission will continue," said Professor Ouyang Renrong, former chairman of the Chinese Hematology and the Shanghai Hematology Societies. "The center, led by Dr. Richard Irons, will continue its journey in China to provide clinical services and research efforts in the field of hematology."
China is making research and development a priority and this move is aligned with the recent meeting of China's 17th Party Congress where continued scientific innovation was a major theme.
Cinpathogen is a major partner in the Fudan-Cinpathogen Clinical and Molecular Research Center at the Institutes of Biomedical Sciences at Fudan University, integrating basic and clinical research, modern diagnostic laboratories and access to one of the largest tissue banks dedicated to diseases of the blood and immune systems.
If you'd like more information about this topic or Cinpathogen, please contact Dr. Richard D. Irons at (303) 381-2543 or email him at email@example.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Cinpathogen Inc.|
Copyright©2008 PR Newswire.
All rights reserved